WallStSmart

Fox Corp Class B (FOX)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 277% more annual revenue ($62.58B vs $16.58B). PFE leads profitability with a 12.4% profit margin vs 11.4%. FOX appears more attractively valued with a PEG of 11.99. FOX earns a higher WallStSmart Score of 51/100 (C-).

FOX

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 7.0Value: 4.7Quality: 8.0
Piotroski: 5/9Altman Z: 2.44

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FOXSignificantly Overvalued (-95.5%)

Margin of Safety

-95.5%

Fair Value

$28.36

Current Price

$52.35

$23.99 premium

UndervaluedFair: $28.36Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FOX2 strengths · Avg: 8.0/10
P/E RatioValuation
12.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

FOX4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
2.0%4/10

2.0% revenue growth

PEG RatioValuation
11.992/10

Expensive relative to growth rate

EPS GrowthGrowth
-35.8%2/10

Earnings declined 35.8%

Free Cash FlowQuality
$-773.00M2/10

Negative free cash flow — burning cash

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : FOX

The strongest argument for FOX centers on P/E Ratio, Price/Book.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : FOX

The primary concerns for FOX are Revenue Growth, PEG Ratio, EPS Growth.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

FOX profiles as a value stock while PFE is a declining play — different risk/reward profiles.

FOX carries more volatility with a beta of 0.54 — expect wider price swings.

FOX is growing revenue faster at 2.0% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

FOX scores higher overall (51/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fox Corp Class B

COMMUNICATION SERVICES · ENTERTAINMENT · USA

Fox Corporation is an American mass media company headquartered in New York City.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?